Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.

Autor: Stuart ASV; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom., Virta M; Tampere University, Tampere, Finland., Williams K; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Seppa I; Tampere University, Tampere, Finland., Hartvickson R; Axtell Clinic, Newton, Kansas, USA., Greenland M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom., Omoruyi E; Janssen Infectious Diseases, Beerse, Belgium., Bastian AR; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Haazen W; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Salisch N; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Gymnopoulou E; Janssen Infectious Diseases, Beerse, Belgium., Callendret B; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Faust SN; NIHR Southampton Clinical Research Facility and NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, United Kingdom., Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.; Oxford NIHR - Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Heijnen E; Janssen Vaccines & Prevention BV, Leiden, The Netherlands.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2022 Dec 28; Vol. 227 (1), pp. 71-82.